Literature DB >> 36147402

The diagnostic utility of rheumatoid factor and anticitrullinated protein antibody for rheumatoid arthritis in the Indian population.

Abhishek Kumar1, Vivek Vasdev2, Saroj Kumar Patnaik3, Satyam Bhatt4, Ramakant Singh5, Aprajita Bhayana6, Arun Hegde7, Ashwani Kumar8.   

Abstract

Background: There is lack of Indian data on diagnostic utility of rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) for diagnosis of rheumatoid arthritis (RA) and prevalence of these antibodies in patients with RA and the healthy population. The study was aimed to assess the diagnostic utility and prevalence of RF and ACPA at different titers in the Indian scenario. Method: All the patients of RA fulfilling the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2010 classification criteria and age and gender-matched healthy controls were included in the study. RF and ACPA were measured by nephelometry and the enzyme-linked immunosorbent assay (ELISA) method, respectively. Result: Of 803 patients (291 men and 512 women) included, the RF was positive in 566 (70.5%) study patients. The ACPA was positive in 527 (71.7%) patients of 735 of them. Among 408 healthy controls, 45 (11%) were RF positive and 19 (4.7%) were ACPA positive.At the positive cutoff level, the RF had a specificity of 87.6% (95% confidence interval [CI] = 84.4-90.8; positive likelihood ratio [LR+] 5.7). Specificity at 2 and 3 times above the upper limit of normal (ULN) increased to 96.2% (95% CI = 94.3-98.1; LR+ 15.7) and 97.1% (95% CI = 95.5-98.7; LR+ 17.1), respectively.The specificity of ACPA at the positive cutoff level was 94.4% (95% CI = 92.2-96.6; LR+ 12.7), which increased to 98% (95% CI = 96.6-99.4), at 2xULN level. The likelihood ratio for ACPA at all cutoff levels measured was more than 10.
Conclusion: The sensitivity and specificity of RF and ACPA in our study population are comparable with those of other studies. ACPA at lower titers may have sufficient diagnostic utility for RA in an appropriate clinical setting.
© 2020 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  Anticitrullinated protein antibody; Diagnosis; Rheumatoid arthritis; Rheumatoid factor; Sensitivity and specificity

Year:  2020        PMID: 36147402      PMCID: PMC9485759          DOI: 10.1016/j.mjafi.2020.04.007

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  26 in total

1.  Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.

Authors:  T R Mikuls; J R O'Dell; J A Stoner; L A Parrish; W P Arend; J M Norris; V M Holers
Journal:  Arthritis Rheum       Date:  2004-12

2.  Interstitial lung disease and neuropathy as predominant extra-articular manifestations in patients with rheumatoid arthritis: a prospective study.

Authors:  Anurag Bharadwaj; Nigil Haroon
Journal:  Med Sci Monit       Date:  2005-09-26

3.  How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.

Authors:  Aase Haj Hensvold; Thomas Frisell; Patrik K E Magnusson; Rikard Holmdahl; Johan Askling; Anca Irinel Catrina
Journal:  Ann Rheum Dis       Date:  2016-04-28       Impact factor: 19.103

4.  Is there an urban-rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan model.

Authors:  Vaijayanti Lagu Joshi; Arvind Chopra
Journal:  J Rheumatol       Date:  2009-02-04       Impact factor: 4.666

5.  Subclinical atherosclerosis in rheumatoid arthritis in India.

Authors:  Sundeep Grover; Ramanand Prasad Sinha; Uttam Singh; Satyendra Tewari; Amita Aggarwal; Ramnath Misra
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

6.  Compound heterozygosity of HLA-DR4 and DR1 antigens in Asian Indians increases the risk of extra-articular features in rheumatoid arthritis.

Authors:  S Agrawal; A Aggarwal; S Dabadghao; S Naik; R Misra
Journal:  Br J Rheumatol       Date:  1995-01

Review 7.  Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.

Authors:  Kunihiro Nishimura; Daisuke Sugiyama; Yoshinori Kogata; Goh Tsuji; Takashi Nakazawa; Seiji Kawano; Katsuyasu Saigo; Akio Morinobu; Masahiro Koshiba; Karen M Kuntz; Isao Kamae; Shunichi Kumagai
Journal:  Ann Intern Med       Date:  2007-06-05       Impact factor: 25.391

8.  Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database.

Authors:  T Sokka; H Kautiainen; T Pincus; S Toloza; G da Rocha Castelar Pinheiro; J Lazovskis; M L Hetland; T Peets; K Immonen; J F Maillefert; A A Drosos; R Alten; C Pohl; B Rojkovich; B Bresnihan; P Minnock; M Cazzato; S Bombardieri; S Rexhepi; M Rexhepi; D Andersone; S Stropuviene; M Huisman; S Sierakowski; D Karateev; V Skakic; A Naranjo; E Baecklund; D Henrohn; F Gogus; H Badsha; A Mofti; P Taylor; C McClinton; Y Yazici
Journal:  Ann Rheum Dis       Date:  2009-07-30       Impact factor: 19.103

9.  Usefulness of anti -CCP antibodies in rheumatic diseases in Indian patients.

Authors:  Rajiva Gupta; Molly M Thabah; Ritu Aneja; Ashok Kumar; Titus Varghese; P J Chandrasenan
Journal:  Indian J Med Sci       Date:  2009-03

10.  Elevated rheumatoid factor and long term risk of rheumatoid arthritis: a prospective cohort study.

Authors:  Sune F Nielsen; Stig E Bojesen; Peter Schnohr; Børge G Nordestgaard
Journal:  BMJ       Date:  2012-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.